{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"The Emerging Biotech Leader","title":"Following a Drug Through Development In Pursuit of a Passion - Victoria Niklas : 21","html":"","width":"100%","height":180,"duration":2315,"description":"“I will always have deep empathy for patients and want to do the best that I can, but I feel very satisfied that I'm driving development of OHB 607, which has the potential to change the trajectory. So, I don't have to sit and remind myself why I'm doing that–there are patients on the other end.” Victoria NiklasHow can you break into biotech from academia without guilt, fear, or self-doubt? After listening to our guest, Victoria Niklas, in Episode 23 of the Emerging Biotech Leader, you may just have the answer to that question. Victoria is the Chief Medical Officer at Oak Hill Bio. As you’ll soon learn, she has been in pharma and biotech just shy of 10 years–7 to be exact. Prior to this time, Victoria was an academic neonatologist and translational scientist beginning at UCLA, rising through the ranks at the University of Virginia in Charlottesville, Children's Hospital of Los Angeles, and finally returning to UCLA before taking her first industry role with Prolacta Bioscience as their first Chief Medical and Scientific Officer. In addition to our new guest and a new topic–we have a new guest host: SSI President Adam Schwartz, who is joined by Ramin. True to form, both get Victoria to open up and share more on the uncertainty and upside in pursuing a new path, especially in making the transition from academia to pharma to biotech. As a preview of what’s to come, Victoria shares more on:The skills she leveraged to make this career jump How to keep an open mind and disregard stigmas about one sector vs. the other Her experience in establishing a licensing agreement, along with the regulatory components of that The role of the CMO Embracing lifelong learning No matter your career crossroads–big Pharma to biotech, academia to biotech, bedside medicine to biotech, we know you’ll find this interview invaluable.  From One Sector To The Other - In Pursuit of ImpactWhile it’s still evolving some seven years in, Victoria’s pharma career includes a background in research...","thumbnail_url":"https://img.transistorcdn.com/ifry0mqC60CO4NUZn9GSCTvcoZ9yKEWu4twnqKmJQQ0/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS80NzEy/MTZiMmZlODIyZDI4/OTliMGJiOWQ0ZDUx/MDhmNi5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}